Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.54 |
| ▸ | CCR5 | P51681 | 3/20 | 0.54 |
| ▸ | CCR8 | P51685 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15870950 | 0.84 | LMNA (0.50) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL5857429 | 0.80 | KDM4E (0.50) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL24060233 | 0.79 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2129888 | 0.79 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL194281 | 0.79 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL16307963 | 0.79 | MMP2 (0.50) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL27822917 | 0.78 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| Water SCHEMBL28278303 | 0.78 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL9000723 | 0.76 | KDM4E (0.50) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL9000718 | 0.76 | KDM4E (0.50) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138810-B | UV patternable polymer blend for organic thin film transistor | 康宁股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11917897-B2 | Photo-patternable organic semiconductor (OSC) polymers for organic thin-film transistors | CORNING INCORPORATED (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117222235-A | Pseudo-homogeneous photopatternable semiconducting polymer blends for Organic Thin Film Transistors (OTFTs) | 康宁股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023235181-A1 | PSEUDO-HOMOGENEOUS PHOTO-PATTERNABLE SEMICONDUCTING POLYMER BLENDS FOR ORGANIC THIN-FILM TRANSISTORS (OTFT) | CORNING INCORPORATED (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11780841-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | IRIMAJIRI THERAPEUTICS INC. (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-111770926-B | Tricyclic compounds, compositions and pharmaceutical uses thereof | 因佩蒂斯生物科学有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11643379-B2 | Synthesis of branched alkyl alcohols by Cu(I)-catalyzed C-C coupling between alkyl Grignard reagents and alkyl tosylates | CORNING INCORPORATED (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-6713650-B2 | ELEVATES ATP BINDING CASSETTE TRANSPORTER 1 EXPRESSION THEREBY INCREASING EFFLUX OF CHOLESTEROL FROM CELLS BY ACTIVE TRANSFER INTO HIGH DENSITY LIPOPROTEINS | CV THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1377283-A2 | COMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003103651-A1 | COMPOUNDS OF THE FORMU;A R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CAD OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20020082257-A1 | ABCA-1 Elevating compounds | CV THERAPEUTICS, INC. | 2002-06-27 | — | — | US | disclosed |
| WO-2002046141-A2 | COUMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | KDM4E 4632/4885LMNA 381/4885CCR1 1772/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4096/4885LMNA 4044/4885CCR1 1209/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4096/4885LMNA 4044/4885CCR1 1209/4885 |
| US-11780841-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | AVPR1B, AVPR2, F12 | KDM4E 663/4885LMNA 1940/4885CCR1 1120/4885 |
| US-11643379-B2 | Synthesis of branched alkyl alcohols by Cu(I)-catalyzed C-C coupling between alkyl Grignard reagents and alkyl tosylates | ADH1C, UGCG, ADH1A | KDM4E 2947/4885LMNA 1476/4885CCR1 144/4885 |
| US-20020082257-A1 | ABCA-1 Elevating compounds | ABCD3, ABCE1, ABCB4 | KDM4E 4506/4885LMNA 1603/4885CCR1 1452/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | KDM4E 3863/4885LMNA 2965/4885CCR1 2891/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | KDM4E 4632/4885LMNA 381/4885CCR1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.